# Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

Study · id `cardio:ct-nct04429503` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04429503](<https://clinicaltrials.gov/study/NCT04429503>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04429503

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 660 participants.

## Technical summary

Registry record NCT04429503. Randomized; quadruple masking; primary purpose treatment. Start 2020-06-29 (actual); primary completion 2022-05-30 (actual). Results posted on 2023-11-21.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 660 participants (enrolled count; ClinicalTrials.gov record NCT04429503, source copy `cardio:ctgov-nct04429503-2025-08-08`, retrieved 2026-10-26)
- Started: 2020-06-29 (actual) (ClinicalTrials.gov record NCT04429503, source copy `cardio:ctgov-nct04429503-2025-08-08`, retrieved 2026-10-26)
- Primary completion: 2022-05-30 (actual) (ClinicalTrials.gov record NCT04429503, source copy `cardio:ctgov-nct04429503-2025-08-08`, retrieved 2026-10-26)
- Completion: 2024-06-18 (actual) (ClinicalTrials.gov record NCT04429503, source copy `cardio:ctgov-nct04429503-2025-08-08`, retrieved 2026-10-26)
- Results first posted: 2023-11-21 (ClinicalTrials.gov record NCT04429503, source copy `cardio:ctgov-nct04429503-2025-08-08`, retrieved 2026-10-26)
- Countries: United States; Canada; Czechia; Germany; Hungary; Japan; Puerto Rico; United Kingdom (ClinicalTrials.gov record NCT04429503, source copy `cardio:ctgov-nct04429503-2025-08-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04429503-2025-08-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
- Acronym: PHOTON
- Condition: Diabetic Macular Edema
- Condition: Type 1 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): aflibercept
- Intervention (Drug): High-dose aflibercept
- Lead sponsor: Regeneron Pharmaceuticals
- Lead sponsor class: INDUSTRY
- Collaborator: Bayer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial (`cardio:pubmed-38461843`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial (`cardio:pubmed-41452566`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial (`cardio:pubmed-41223900`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c266333befb41c33c366448805c0a34ac2260fd799939fa3d67bf4347156ee68
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
